ArticleScientific reports2025
Evaluating Xanthomonas oryzae pv. oryzae (Xoo) infection dynamics in rice for distribution routes and environmental reservoirs by molecular approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cross-tolerance as an ecological paradox: a hypothesis-driven systematic review of Leersia hexandra as both remediator and pathogen reservoir.Oecologia · 2026Pooled it
- Molecular Bases and Genetic Design of Rice Disease Resistance for Optimized Yield and Sustainable Agriculture.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Metal-driven nanoassembly of hexahistidine-tagged melittin enables superior phytopathogen biofilm degradation with attenuated toxicity.Journal of nanobiotechnology · 2026Article
- Review
- Molecular and phenotypic diversity of bacterial leaf blight resistance in green super rice germplasm.BMC plant biology · 2026Article
- Mechanism ofFrontiers in microbiology · 2026Article
- Prime editing: a new frontier in precision genome engineering for rice improvement.Frontiers in plant science · 2026Review
- Plant-Based ZnO Nanoparticles for Green Nanobiocontrol of a Highly Virulent Bacterial Leaf Blight Pathogen: Mechanistic Insights and Biocompatibility Evaluation.Nanomaterials (Basel, Switzerland) · 2025Article
- Endophytic Bacterial Community Structure and Function Response of BLB Rice Leaves After Foliar Application of Cu-Ag Nanoparticles.Nanomaterials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Xanthomonas oryzae pv. oryzae (Xoo) is a bacterial pathogen responsible for bacterial leaf blight (BLB) in rice, which can result in significant yield losses of up to 70%. A study evaluated the spread of Xoo in rice fields using environmental samples and employed colorimetric loop-mediated amplification (cLAMP) and PCR for detection. Quantitative PCR (qPCR) was used to measure infection levels. The research compared infection severity between a susceptible rice variety, Phitsanulok 2 (PSL2), and a resistant variety, PSL2-Xa21. Results showed that Xoo infection decreased from the leaves to the roots, but the bacteria persisted in soil and water for up to 12 and 6 weeks, respectively. The cLAMP assay, with the LpXoo4009 primer, effectively detected Xoo at low concentrations in both soil and water. Additionally, common grasses found in rice fields, such as Eriochloa procera, Echinochloa crus-galli and Chloris barbata were identified as temporary reservoirs for Xoo, facilitating its spread. The Xoo pathogen is distributed from infected leaves to roots and then from roots to the soil and nearby water. Grasses in the fields contribute to the perpetuation of the infection cycle serving as potential reservoirs that maintain the pathogen's presence in the environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.